Display Settings:

Format
Items per page

Send to:

Choose Destination

Results: 1 to 20 of 76

1.

Atypical hemolytic uremic syndrome

MedGen UID:
444141
Concept ID:
C2931788
Disease or Syndrome
2.

eculizumab

A humanized monoclonal antibody directed against terminal complement protein C5. Eculizumab binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and blocking the complement-mediated destruction of paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. (NCI05) [from NCI]

MedGen UID:
323806
Concept ID:
C1541483
Pharmacologic Substance
3.

Hemolytic uremic syndrome

A form of thrombotic microangiopathy with renal failure, hemolytic anemia, and severe thrombocytopenia. [from NCI]

MedGen UID:
42403
Concept ID:
C0019061
Disease or Syndrome
4.

Syndrome

A set of symptoms or conditions that occur together and suggest the presence of a certain disease or an increased chance of developing the disease. [from NCI]

MedGen UID:
11688
Concept ID:
C0039082
Disease or Syndrome
5.

Hemolytic-uremic syndrome

MedGen UID:
505834
Concept ID:
CN004936
Finding
6.

Atypical hemolytic-uremic syndrome 5

Hemolytic-uremic syndrome (HUS) is characterized by hemolytic anemia, thrombocytopenia, and renal failure caused by platelet thrombi in the microcirculation of the kidney and other organs. Typical (acquired) HUS is triggered by infectious agents such as strains of E. coli (Stx-E. coli) that produce powerful Shiga-like exotoxins, whereas atypical HUS (aHUS) can be genetic, acquired, or idiopathic (of unknown cause). Onset of atypical HUS ranges from prenatal to adulthood. Individuals with genetic atypical HUS frequently experience relapse even after complete recovery following the presenting episode. Sixty percent of genetic aHUS progresses to end-stage renal disease (ESRD). [from GeneReviews]

MedGen UID:
442875
Concept ID:
C2752037
Finding
7.

atypical hemolytic-uremic syndrome

Hemolytic-uremic syndrome (HUS) is characterized by hemolytic anemia, thrombocytopenia, and renal failure caused by platelet thrombi in the microcirculation of the kidney and other organs. Typical (acquired) HUS is triggered by infectious agents such as strains of E. coli (Stx-E. coli) that produce powerful Shiga-like exotoxins, whereas atypical HUS (aHUS) can be genetic, acquired, or idiopathic (of unknown cause). Onset of atypical HUS ranges from prenatal to adulthood. Individuals with genetic atypical HUS frequently experience relapse even after complete recovery following the presenting episode. Sixty percent of genetic aHUS progresses to end-stage renal disease (ESRD). [from GeneReviews]

MedGen UID:
431595
Concept ID:
CN043568
Disease or Syndrome
8.

Atypical hemolytic-uremic syndrome 4

Hemolytic-uremic syndrome (HUS) is characterized by hemolytic anemia, thrombocytopenia, and renal failure caused by platelet thrombi in the microcirculation of the kidney and other organs. Typical (acquired) HUS is triggered by infectious agents such as strains of E. coli (Stx-E. coli) that produce powerful Shiga-like exotoxins, whereas atypical HUS (aHUS) can be genetic, acquired, or idiopathic (of unknown cause). Onset of atypical HUS ranges from prenatal to adulthood. Individuals with genetic atypical HUS frequently experience relapse even after complete recovery following the presenting episode. Sixty percent of genetic aHUS progresses to end-stage renal disease (ESRD). [from GeneReviews]

MedGen UID:
416691
Concept ID:
C2752038
Finding
9.

Atypical hemolytic-uremic syndrome 3

Hemolytic-uremic syndrome (HUS) is characterized by hemolytic anemia, thrombocytopenia, and renal failure caused by platelet thrombi in the microcirculation of the kidney and other organs. Typical (acquired) HUS is triggered by infectious agents such as strains of E. coli (Stx-E. coli) that produce powerful Shiga-like exotoxins, whereas atypical HUS (aHUS) can be genetic, acquired, or idiopathic (of unknown cause). Onset of atypical HUS ranges from prenatal to adulthood. Individuals with genetic atypical HUS frequently experience relapse even after complete recovery following the presenting episode. Sixty percent of genetic aHUS progresses to end-stage renal disease (ESRD). [from GeneReviews]

MedGen UID:
414542
Concept ID:
C2752039
Disease or Syndrome
10.

Atypical hemolytic-uremic syndrome 2

Hemolytic-uremic syndrome (HUS) is characterized by hemolytic anemia, thrombocytopenia, and renal failure caused by platelet thrombi in the microcirculation of the kidney and other organs. Typical (acquired) HUS is triggered by infectious agents such as strains of E. coli (Stx-E. coli) that produce powerful Shiga-like exotoxins, whereas atypical HUS (aHUS) can be genetic, acquired, or idiopathic (of unknown cause). Onset of atypical HUS ranges from prenatal to adulthood. Individuals with genetic atypical HUS frequently experience relapse even after complete recovery following the presenting episode. Sixty percent of genetic aHUS progresses to end-stage renal disease (ESRD). [from GeneReviews]

MedGen UID:
414167
Concept ID:
C2752040
Finding
11.

Atypical hemolytic-uremic syndrome 1

Hemolytic-uremic syndrome (HUS) is characterized by hemolytic anemia, thrombocytopenia, and renal failure caused by platelet thrombi in the microcirculation of the kidney and other organs. Typical (acquired) HUS is triggered by infectious agents such as strains of E. coli (Stx-E. coli) that produce powerful Shiga-like exotoxins, whereas atypical HUS (aHUS) can be genetic, acquired, or idiopathic (of unknown cause). Onset of atypical HUS ranges from prenatal to adulthood. Individuals with genetic atypical HUS frequently experience relapse even after complete recovery following the presenting episode. Sixty percent of genetic aHUS progresses to end-stage renal disease (ESRD). [from GeneReviews]

MedGen UID:
412743
Concept ID:
C2749604
Finding
12.

Recurrence (disease attribute)

The return of a sign, symptom, or disease after a remission. [from MeSH]

MedGen UID:
416712
Concept ID:
C2825055
Pathologic Function
13.

mycophenolate mofetil

A drug used to prevent graft-versus-host disease (GVHD) after organ transplants. It is also being studied in the prevention of GVHD after stem cell transplants for cancer, and in the treatment of some autoimmune disorders. Mycophenolate mofetil is a type of immunosuppressive agent. [from NCI]

MedGen UID:
60443
Concept ID:
C0209368
Pharmacologic Substance
14.

Tacrolimus

A drug used to help reduce the risk of rejection by the body of organ and bone marrow transplants. [from NCI_NCI-GLOSS]

MedGen UID:
43111
Concept ID:
C0085149
Pharmacologic Substance
15.

Disease

Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function. [from NCI]

MedGen UID:
4347
Concept ID:
C0012634
Disease or Syndrome
16.

disease

MedGen UID:
798428
Concept ID:
CN204926
Disease or Syndrome
17.

Complement inhibitor

serum proteins which act at key sites in the complement sequence to modulate or prevent the progression of the reaction; absence of these factors leads to uncontrolled activation of the complement system with accompanying disease; can apply to endogenous or exogenous substances. [from CRISP]

MedGen UID:
507583
Concept ID:
C0009543
Pharmacologic Substance
18.

Multiple endocrine neoplasia, type 2

Multiple endocrine neoplasia type 2 (MEN 2) is classified into three subtypes: MEN 2A, FMTC (familial medullary thyroid carcinoma), and MEN 2B. All three subtypes involve high risk for development of medullary carcinoma of the thyroid (MTC); MEN 2A and MEN 2B have an increased risk for pheochromocytoma; MEN 2A has an increased risk for parathyroid adenoma or hyperplasia. Additional features in MEN 2B include mucosal neuromas of the lips and tongue, distinctive facies with enlarged lips, ganglioneuromatosis of the gastrointestinal tract, and an asthenic ‘marfanoid’ body habitus. MTC typically occurs in early childhood in MEN 2B, early adulthood in MEN 2A, and middle age in FMTC. [from GeneReviews]

MedGen UID:
441301
Concept ID:
CN073359
Disease or Syndrome
19.

Disease Response

The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression. [from NCI]

MedGen UID:
309976
Concept ID:
C1704632
Finding
20.

Complement inhibitor

serum proteins which act at key sites in the complement sequence to modulate or prevent the progression of the reaction; absence of these factors leads to uncontrolled activation of the complement system with accompanying disease; can apply to endogenous or exogenous substances. [from CRISP]

MedGen UID:
297405
Concept ID:
C1564892
Pharmacologic Substance

Display Settings:

Format
Items per page

Send to:

Choose Destination

Supplemental Content

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...